SyntheticMR Receives Regulatory Approval for their Innovative SyMRI Software Solution in South Korea

SyntheticMR announced today that their quantitative imaging software solution SyMRI 12.1 has received regulatory approval in South Korea according to KFDA (Korea Food & Drug Administration). This means that SyMRI 12.1 now can be sold and distributed in this market. 

“This approval for SyMRI 12.1 creates vital opportunities for us to develop our market presence in South Korea, which is one of our focus markets. We already have an established customer base in the region” says Ulrik Harrysson, CEO at SyntheticMR. “We have also seen a growing interest for our products in the region, which is very exciting, and we look forward to distributing SyMRI 12.1 to supply radiologists with new insights and show in practice how our unique technology can transform the MRI workflow.” 

SyMRI NEURO is designed to help you save valuable time by reducing scan time, all the while aiding as an objective decision support for diagnosis and patient follow-ups. A single fast scan offers a fast and standardized protocol with clinically relevant quantitative data for more robust assessments of patients. Additionally, SyMRI NEURO provides automatic segmentation of tissue such as myelin volumes, quantification of white matter, gray matter, cerebrospinal fluid and brain parenchymal volume. 

SyMRI MSK provides more information in less time. One single fast scan produces quantitative T1, T2, and PD maps and a series of contrast-weighted images, for both clinical use and advanced research. SyMRI MSK also gives the radiologist more control over the image quality by making it possible to change TE, TR, and TI post-scan.